Fact CheckerSign in

NCT05528484Recruiting

Self-reported Outcomes of Patients in ERAS Nursing

Effect of ERAS Nursing on Self-reported Outcomes of Patients Undergoing Minimally Invasive Lung Cancer Surgery

Source: ClinicalTrials.gov · Last updated 16 Nov 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

We aimed to evaluate the effect of ERAS nursing program on self-reported outcomes of patients undergoing minimally invasive lung cancer surgery, and compared the differences in length of hospital stay, complications, and readmission rate between ERAS and non-ERAS nursing programs

Status (registry)
Recruiting
Study type
Interventional
Enrollment
600 (estimated)
First submitted
1 Sept 2022
Start date
Oct 2019
Primary completion date
Jun 2023
Lead sponsor
The Second Hospital of Shandong University
Diseases
Lung cancer
NCT number
NCT05528484

What you commit to

  • Study type: Interventional
  • Planned participants: 600
  • From Oct 2019 to the primary completion date, Jun 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Pneumonectomy was performed and converted to open surgery
    • Surgery intensive care, unable to cooperate (language
    • Speech disorders, psychopathology)

Who the study is looking for

  • ≥18years,Minimally invasive elective surgery,cooperate

Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Second Hospital of Shandong University
Coordinator of this site? Confirm its status		JinanChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.